Fulcrum has assembled a team of leaders from the biopharmaceutical industry. Together they combine experiences in drug discovery and development with a steadfast dedication to making a positive impact in the lives of patients and their families.
Robert J. Gould, Ph.D.
President and Chief Executive Officer, Board Member
Robert Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at the Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. Throughout his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a B.A. from Spring Arbor College and a Ph.D. from the University of Iowa and completed postdoctoral studies at the Johns Hopkins University.
“I joined Fulcrum because I know of no greater calling than to translate advances in science into potentially transformative medicines for patients with rare genetic diseases.”
Owen Wallace, Ph.D.
Chief Scientific Officer
Owen Wallace joined Fulcrum in April 2017. He has more than two decades of experience in drug discovery and development across multiple therapeutic areas, including neuroscience, endocrine, infectious-, respiratory- and rare- diseases. He is the co-inventor of 7 clinical candidates, and has overseen teams who have progressed more than 30 compounds into clinical development. Prior to joining Fulcrum, Owen served as Head, Global Discovery Chemistry at Novartis, where he was responsible for teams and projects across multiple sites in several disease areas and the chemical genetics field. Prior to Novartis, he was the Site Scientific Leader with Eli Lilly & Company in the United Kingdom leading a cross-functional team focusing on Alzheimer’s disease and schizophrenia. Before that, he held research positions at Bristol-Myers Squibb, where he co-initiated a program on a novel mechanism for inhibiting HIV infection that is now in Phase 3 clinical trials. Owen earned his Ph.D. in chemistry from Yale University.
“I joined Fulcrum to make a difference, to be a member of a team dedicated to providing solutions for patients and their families suffering from diseases where there are few answers.”
Chief Financial Officer
Amit Hasija joined Fulcrum as chief financial officer in April 2017, bringing more than two decades of executive leadership experience in commercial operations, business development and corporate finance within the health care industry. Amit was most recently at Sanofi where his roles included VP and Head of Integrated Care, leading value-based contracting for the U.S., and VP and Head of business development for North America. Prior to joining Sanofi, Amit spent more than a decade as an investment banker with Goldman Sachs, Credit Suisse and Deutsche Bank, where he executed mergers and acquisitions and corporate finance transactions for healthcare clients. Amit began his career at Merck in vaccine manufacturing as a planning and logistics analyst and operations manager. He earned a B.S. in chemical engineering from Drexel University and received an MBA from New York University’s Stern School of Business.
“The team at Fulcrum opened my eyes to a new approach to drug discovery. I joined because I believe that precision medicine can bring new therapies to patients with diseases previously thought to be incurable.”
Angela M. Cacace, Ph.D.
Vice President, Biology
Angela Cacace joined Fulcrum at the company’s launch in 2016 with over 20 years of experience in pharmaceutical research contributing to the early discovery of 16 molecules and their advancement into clinical development. Most recently, she was a director of genetically defined diseases at Bristol-Myers Squibb (BMS), leading a biology team focused on genetic neurologic and skeletal muscle disorders. Also while at BMS, she served as a director of exploratory neurosciences and applied genomics, and established and led teams that worked across research, including the Cellular Resource Group, the GPCR Hit Identification Group and the Lead Profiling (ADMET) Teams. During a sabbatical from BMS, Angela worked in the cancer biology group at Pfizer. Angela received a B.S. from Fairfield University, obtained her Ph.D. in pharmacology from Columbia University and completed her postdoctoral training at the National Cancer Institute.
“I joined Fulcrum because of a strong sense of compassion for patients and their families who suffer from devastating rare childhood genetic disorders and a commitment to bring them disease-modifying treatments.”
Diego Cadavid, M.D.
Vice President, Clinical Development
Diego Cadavid joined Fulcrum in September 2016. He brings more than 17 years of experience in academic and biotechnology and pharmaceuticals research and drug development. Prior to joining Fulcrum Therapeutics, Diego was at Biogen for nearly 9 years where he was Senior Medical Director in the MS Clinical Development Group and lead of the CNS Remyelination Team. During much of his time at Biogen Diego was also consultant at the Center for Immunology and Inflammatory Diseases at the Massachusetts General Hospital in Boston. Before joining Biogen, Diego spent 9 years in academia at Rutgers-New Jersey Medical School where he was Associate Professor of Neurology and Neuroscience and worked on basic research on spirochetal brain infections and clinical research in Multiple Sclerosis. Diego completed postdoctoral research in Microbiology and Immunology and Internship in Internal Medicine at the University of Texas Health Science Center in San Antonio, Neurology Residency Training at Georgetown University Hospitals, and Neuropathology Fellowship at the Armed Forces Institute of Pathology. Diego holds an MD from Universidad Javeriana in Bogota, Colombia.
“I came to Fulcrum Therapeutics to join forces with a talented multidisciplinary drug development team to transform the new learnings from epigenetic gene regulation and stem cell biology into transformative treatments for genetically validated diseases with high unmet need.”
Lucienne Ronco, Ph.D.
Vice President, Translational Medicine
Lucienne Ronco joined Fulcrum at the company’s launch in 2016. She brings more than 17 years of industry experience in translational medicine, drug discovery, biotechnology and pharmaceuticals. Prior to joining Fulcrum, Lucienne was a director within the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard. Prior to her work at the Broad Institute, she was president of research at Catabasis Pharmaceuticals. Previously in her career, Lucienne worked for 10 years at AstraZeneca Boston, where she held positions of increasing responsibility, including global director of translational medicine, local director for the departments of in vivo pharmacology, informatics and disease area research, and the breast disease team scientific lead. Prior to AstraZeneca, she was a senior research investigator at the Pfizer Discovery Technology Center. Lucienne completed postdoctoral research at Harvard Medical School. She holds a Ph.D. in biological chemistry from the University of California, Los Angeles.
“I joined Fulcrum because I believe we can impact these very challenging diseases and bring real improvement to the lives of patients and their families.”
Aaron Chang, Ph.D.
Senior Director, Computational Biology
Aaron Chang joined Fulcrum in 2016 bringing over 15 years of experience. He was previously Executive Director of the Center for Computational Biology and Bioinformatics (CCBB) at UC San Diego bringing together omics analysis, systems biology and cloud computing to over 100 research groups. He was also an Associate Investigator at the Baylor Institute for Immunology Research heading a bioinformatics group involved in translational research efforts centered on cancer vaccine and liver transplantation studies. Aaron served as Associate Director of Computational Biology at Regulus Therapeutics during its initial startup phase. His group there identified several key miRNA targets currently in clinical development. At Rosetta Inpharmatics (Merck), he was a member of the Pathway Informatics team that developed the first in-house systems biology tools for target identification. Aaron was a National Library Medicine Postdoctoral Fellow in Biomedical Informatics at the University of Washington. He completed his Ph.D. in Genetics at Harvard University working on transcription factors governing hematopoiesis. He holds an S.B in Biology from MIT.
"I joined Fulcrum because of the opportunity to leverage the latest computational approaches in genomics and systems biology to realize precision medicine in genetic diseases. Using data mining to enable real patient impact is very rewarding.”
Lorin (Drew) Thompson, Ph.D.
Senior Director, Molecular Sciences
Lorin (Drew) Thompson joined Fulcrum shortly after launch in summer, 2016 and brings more than 18 years of experience in medicinal chemistry to the Molecular Sciences organization. Drew joined Fulcrum from Bristol-Myers Squibb, where he led both early- and full-phase drug discovery programs in both neuroscience and genetically-defined diseases. As a project team leader, teams under Drew’s direction nominated 2 IND candidates including an allosteric modulator of gamma secretase targeting Alzheimer’s disease and an NR2B-selective NAM for treatment-resistant depression. He also helped establish the discovery chemistry platforms group and served on the leadership team while guiding chemistry efforts around phenotypic screening and target identification. Now with Fulcrum he leads the team responsible for characterization of molecular targets including medicinal chemistry, structural biology and biophysics, enzymology, and DMPK. Drew holds a Ph. D. from the University of California, Berkeley and a B.S. in chemistry from the University of North Carolina at Chapel Hill.
“I joined Fulcrum because the opportunity to bring disease-modifying therapies to patients with rare genetic diseases is truly inspiring, and Fulcrum has created a unique environment to focus on creating these types of transformative medicines.”
Walter E. Kowtoniuk, Ph.D.
Director, Strategy and Operations
Walt Kowtoniuk joined Fulcrum after serving as a senior associate at Third Rock Ventures where he led the creation of Fulcrum. Walt joined Third Rock in 2013 to focus on new company formation in the rare genetic disease space. While at Third Rock he also supported the partner development team and contributed to the formation of multiple new companies focused on delivering transformative medicines to patients. Prior to joining Third Rock, Walt was a manager at Clarion Healthcare, a boutique strategy consulting firm in the life sciences industry. At Clarion, Walt focused on developing new business strategies and providing commercial insight into early product development in the rare disease space. He has also worked with pre-commercial companies to build and prepare the organization for product commercialization. Walt has a Ph.D. in chemical biology from Harvard University and a B.S. in biochemistry, molecular biology and philosophy from Gettysburg College.
“The advances in understanding gene regulation create an opportunity to develop therapies for previously untreatable diseases. I helped create Fulcrum because of the moral imperative to try to make these therapies a reality.”
Vice President, Human Resources
Kim Hazen joined Fulcrum in September 2017 with over 25 years of experience in Human Resources. Most recently, she was Vice President of Human Resources at Warp Drive Bio, where she led efforts to build a drug discovery culture and core values to match with an emphasis on elite performance. Prior to joining Fulcrum and Warp Drive Bio, Kim served as the Executive Director of Human Resources at Aegerion Pharmaceuticals and as Head of Human Resources at Broad Institute. Before joining the life sciences industry, she worked on the investment side of human resources at Pioneer Investments, Fidelity Investments, Liberty Mutual and Bank of America. Kim received a B.A. in psychology from SUNY Potsdam and her MBA from Boston University.
“At Fulcrum we are all champions for patients with rare genetic diseases; we rally around treating the untreatable. I joined because I want to work with people that are passionate about both the science and the patients we aim to help. THIS is why I am here.”
Vice President, Finance and Accounting
Peter Thomson joined Fulcrum in 2018, bringing over 15 years of experience in the life sciences industry. Most recently, he was a consultant for three Third Rock Ventures portfolio companies, where he served as interim head of finance. Before that, he served as head of finance at BIND Therapeutics, where he was responsible for all finance and accounting activities, developed the corporate valuation for the company and played an integral role in the company’s sale to Pfizer. Prior to BIND, he was senior director of finance at Ovascience and director of finance at Millenium: The Takeda Oncology Company. In addition, he held positions on the finance teams at Boston Scientific Corporation, Infomedics, Inc., and the Hewlett-Packard Company. Peter earned a B.A. from Brown University and an MBA from the University of Chicago Booth School of Business.